![Christopher Alan Keightley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Alan Keightley
Vorstandsvorsitzender bei Pheon Therapeutics Ltd.
Aktive Positionen von Christopher Alan Keightley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Summit (Cambridge) Ltd.
![]() Summit (Cambridge) Ltd. Pharmaceuticals: MajorHealth Technology Summit (Cambridge) Ltd. develops and manufactures drugs and pharmaceuticals. It discovers and develops therapeutics for neurological, ophthalmologic, metabolic, and gastrointestinal diseases. The company was founded in 2001 by Paul Goldsmith and Mark Carlton and is headquartered in Cambridge, the United Kingdom. | Direktor/Vorstandsmitglied | - | - |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Vorstandsvorsitzender | - | - |
Transcriptogen Ltd.
![]() Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Direktor/Vorstandsmitglied | 29.05.2013 | - |
Vorsitzender | - | - |
Karriereverlauf von Christopher Alan Keightley
Ehemalige bekannte Positionen von Christopher Alan Keightley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ADC Products (UK) Ltd.
![]() ADC Products (UK) Ltd. Medical/Nursing ServicesHealth Services ADC Products (UK) Ltd. operates as a clinical stage biotechnology company. It develops pyrrolobenzodiazepines for antibody-drug conjugation. The company was founded in November 2000 and is headquartered in Reading, the United Kingdom. | Direktor/Vorstandsmitglied | - | 28.02.2012 |
I.Q. (BIO) Ltd. | Gründer | - | - |
Lumora Ltd.
![]() Lumora Ltd. Electronic Equipment/InstrumentsElectronic Technology Lumora Ltd. provides molecular diagnostic products for the clinical and industrial markets. The company was founded by Laurence Carlo Tisi and James A. H. Murray in 2002 and is headquartered in Cambridge, the United Kingdom. | Vorsitzender | - | - |
Ausbildung von Christopher Alan Keightley
University of Cambridge | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 8 |
Operativ
Director/Board Member | 3 |
Chairman | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 4 |
Electronic Technology | 2 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
Lumora Ltd.
![]() Lumora Ltd. Electronic Equipment/InstrumentsElectronic Technology Lumora Ltd. provides molecular diagnostic products for the clinical and industrial markets. The company was founded by Laurence Carlo Tisi and James A. H. Murray in 2002 and is headquartered in Cambridge, the United Kingdom. | Electronic Technology |
Summit (Cambridge) Ltd.
![]() Summit (Cambridge) Ltd. Pharmaceuticals: MajorHealth Technology Summit (Cambridge) Ltd. develops and manufactures drugs and pharmaceuticals. It discovers and develops therapeutics for neurological, ophthalmologic, metabolic, and gastrointestinal diseases. The company was founded in 2001 by Paul Goldsmith and Mark Carlton and is headquartered in Cambridge, the United Kingdom. | Health Technology |
ADC Products (UK) Ltd.
![]() ADC Products (UK) Ltd. Medical/Nursing ServicesHealth Services ADC Products (UK) Ltd. operates as a clinical stage biotechnology company. It develops pyrrolobenzodiazepines for antibody-drug conjugation. The company was founded in November 2000 and is headquartered in Reading, the United Kingdom. | Health Services |
I.Q. (BIO) Ltd. | |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Health Technology |
Transcriptogen Ltd.
![]() Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Health Technology |